Gemphire Therapeutics, Inc.

Third quarter biopharmaceutical start-up financings fell 23% from the second quarter, but large individual company financings continue to stand out, including Century Therapeutics with a $250m serie

Alize Pharma III Gets €67m In Series A Round Alize Pharma III SAS raised €67m ($75m) in an oversubscribed Series A financing led by LSP, which was joined by other new backers Novo Ventures, Kurma Pa

Novo Nordisk AS is to team up with Dutch biotech Staten Biotechnology to develop novel treatments for hypertriglyceridaemia, in a deal worth €430m in milestone payments to the latter company, with a

Gemphire Therapeutics Inc. 's lead product, gemcabene, has received a double blow in the past week, sending the firm's stock down by 45% on August 10 to hit an all-time low of $1.80 on Nasdaq. That da